2Background: Alternative polyadenylation (APA) shortens or lengthens the 3ʹ-untranslated region (3ʹ-UTR) of hundreds of genes in cancer. While APA genes modify microRNA target sites in the 3ʹ-UTRs to promote tumorigenesis, previous studies have focused on a subset of the modification landscape.
Method:For comprehensive understanding of the function of global APA events, we consider the total target site landscape of microRNAs that are significantly and collectively modified by global APA genes. To identify such microRNAs in spite of complex interactions between microRNAs and the APA genes, we developed Probabilistic Inference of MicroRNA Target Site Modification through APA (PRIMATA-APA).
Results:Running PRIMATA-APA on TCGA breast cancer data, we identified that global APA events concentrate to modify target sites of particular microRNAs (target-site-modified-miRNA or tamoMiRNA). TamoMiRNAs are enriched for microRNAs known to regulate cancer etiology and treatments. Also, their target genes are enriched in cancer-associated pathways, suggesting that APA modifies target sites of tamoMiRNAs to progress tumors. Knockdown of NUDT21, a master 3ʹ-UTR regulator in HeLa cells, confirmed the causal role of tamoMiRNAs for tumor growth.Conclusions: Further, the expressions of tamoMiRNA target genes, enriched in cancerassociated pathways, vary across tumor samples as a function of patient-specific APA events, suggesting that APA is a novel regulatory axis for interpatient tumor heterogeneity.
BackgroundThe dynamic usage of the messenger RNA 3ʹ-untranslated region (3ʹ-UTR) through alternative polyadenylation (APA) results in transcription of distinct isoforms with shortened or lengthened 3ʹ-UTRs. 3ʹ-UTR lengthening (3ʹUL) was recently reported to regulate cell senescence[1] linked with tumor suppressive pathways such as cell cycle inhibitors and DNA damage markers[2]-[5]. 3ʹ-UTR shortening (3ʹUS) was reported widespread in diverse types of human cancers[6]. Further, the impact of 3ʹUS on prognosis[6] and its association with drug sensitivity[7] suggests clinical implications of APA events in human cancer.We discovered a 3ʹUS trans tumorigenic mechanism[8] based on its interaction with competing-endogenous RNA (ceRNA) [9]. Since 3ʹUS removes microRNA (miRNA) target sites in the distal region of the 3ʹ-UTRs, genes with 3ʹUS event (3ʹUS genes) do not sequester the miRNAs. Since ceRNAs co-regulate each other RNAs through competing for binding miRNAs, the miRNAs released from 3ʹUS would be redirected to the ceRNA partners of the 3ʹUS genes, working to promote tumorigenesis. Recently, we also found that this interactive mechanism between 3ʹUS and ceRNA is involved in the subtype-specific progression of breast cancer [10].However, computational predictions of ceRNA have been limited for RNAs with >5 miRNA target sites [8], [9], [11], [12]. Since such RNAs account for a subset of all expressed genes (e.g. among 17,085 genes with the average HiSeqV2 expression value > 1 across 1,098 TCGA breast tumor samples, 5,258 genes (30.5 %) have...